Q2 Earnings Forecast for VERA Issued By HC Wainwright

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Vera Therapeutics in a research report issued on Monday, May 5th. HC Wainwright analyst A. He anticipates that the company will post earnings of ($0.81) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $75.00 target price on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics' FY2025 earnings at ($3.18) EPS, FY2026 earnings at ($2.32) EPS, FY2027 earnings at $0.83 EPS, FY2028 earnings at $3.30 EPS and FY2029 earnings at $5.37 EPS.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter last year, the firm earned ($0.56) EPS.

Several other research firms have also recently issued reports on VERA. Cantor Fitzgerald reduced their target price on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a research note on Wednesday. Wolfe Research assumed coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective for the company. The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $58.00 target price on the stock. Wedbush reduced their price target on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research report on Wednesday. Finally, Guggenheim lifted their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $63.80.

Vera Therapeutics Stock Up 2.8 %

NASDAQ VERA opened at $22.62 on Thursday. The business's 50-day moving average is $24.48 and its 200 day moving average is $34.98. The stock has a market capitalization of $1.44 billion, a PE ratio of -8.67 and a beta of 1.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics has a 1 year low of $18.53 and a 1 year high of $51.61.

Institutional Trading of Vera Therapeutics

A number of hedge funds have recently made changes to their positions in VERA. Huntington National Bank purchased a new position in Vera Therapeutics during the fourth quarter valued at $26,000. AlphaQuest LLC bought a new position in shares of Vera Therapeutics during the fourth quarter valued at $34,000. GF Fund Management CO. LTD. purchased a new position in shares of Vera Therapeutics in the 4th quarter worth about $56,000. KBC Group NV boosted its stake in Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after purchasing an additional 1,387 shares in the last quarter. Finally, Summit Investment Advisors Inc. grew its position in Vera Therapeutics by 16.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock valued at $196,000 after purchasing an additional 639 shares during the last quarter. 99.21% of the stock is owned by institutional investors.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.